Prevention & lipidsResearch article
Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes
- Target trial emulation
- sequential target trial emulation
- UK primary care data (IQVIA Medical Research Data)
Authors' conclusion
Among adults with T1DM, statin initiation for primary prevention was associated with reductions in all-cause mortality and major CVD with a very low risk of adverse effects.
Study context
- Population
- Adults aged 25–84 years with T1DM on insulin, baseline low-density lipoprotein-cholesterol (LDL-C) ≥2.6 mmol/L or non-HDL cholesterol ≥3.4 mmol/L, without preexisting CAD, MI, stroke, HF or other listed conditions, 2005–2016person-trials
- Participants
- 4,176 vs 16,704
- Comparison
- Statin initiation vs noninitiation
- Statin initiatorsn = 4,176
- Noninitiatorsn = 16,704reference
- Outcome
- All-cause mortality, major cardiovascular disease (CVD) and adverse events (myopathy and liver dysfunction); 10-year absolute risk differences
- Follow-up
- 10 years
Main finding
As reported in the abstract
Statin initiators vs NoninitiatorsRD (95% CI)
all-cause mortality, ITT
−1.66%(−2.79% to −0.45%)
all-cause mortality, per-protocol
−3.48%(−4.68% to −2.07%)
major CVD, ITT
−1.63%(−2.57% to −0.53%)
major CVD, per-protocol
−2.69%(−4.00% to −1.22%)
Further findings
Subgroups
- Absolute risk reductions generally larger in women, persons ≥40 years, baseline LDL-C ≥3.4 mmol/L, and higher predicted CV risk
Safety
Myopathy and liver dysfunction
- Some analyses suggested a slight association with increased risk of liver dysfunction; no association with myopathy
Original publication
Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes. J Am Coll Cardiol. Published 16 September 2025. doi:10.1016/j.jacc.2025.07.013
Summarised from the published abstract; every number is checked against it